Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Twenty-five years of triptans - a nationwide population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To determine whether early treatment with sumatriptan can prevent PACAP38-induced migraine attacks.

METHODS: A total of 37 patients with migraine without aura were enrolled between July 2018 to December 2019. All patients received an intravenous infusion of 10 picomole/kg/min of PACAP38 over 20 min followed by an intravenous infusion of 4 mg sumatriptan or placebo over 10 min on two study days in a randomised, double-blind, placebo-controlled, crossover study.

RESULTS: Of 37 patients enrolled, 26 (70.3%) completed the study and were included in analyses. Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016). There were no differences in area under the curve for headache intensity between sumatriptan (mean AUC 532) and placebo (mean AUC 779) (p = 0.35). Sumatriptan significantly constricted the PACAP38-dilated superficial temporal artery immediately after infusion (T30) compared with infusion of placebo (p < 0.001).Conclusions and relevance: Early treatment with intravenously administered sumatriptan prevented PACAP38-induced migraine. Prevention of migraine attacks was associated with vasoconstriction by sumatriptan in the earliest phases of PACAP provocation. These results suggest that sumatriptan prevents PACAP38-induced migraine by modulation of nociceptive transmission within the trigeminovascular system.Trial Registration: ClinicalTrials.gov (NCT03881644).

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume41
Issue number6
Pages (from-to)731-748
Number of pages18
ISSN0333-1024
DOIs
Publication statusPublished - May 2021

Bibliographical note

Publisher Copyright:
© International Headache Society 2021.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • Blood vessels, PACAP isoforms, headache, mast cell degranulation, serotonin, triptans

ID: 65608247